Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes : A single-centre randomized controlled study

Show full item record



Permalink

http://hdl.handle.net/10138/308850

Citation

Matikainen , N , Söderlund , S , Björnson , E , Pietiläinen , K , Hakkarainen , A , Lundbom , N , Taskinen , M-R & Boren , J 2019 , ' Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes : A single-centre randomized controlled study ' , Diabetes, obesity and metabolism , vol. 21 , no. 1 , pp. 84-94 . https://doi.org/10.1111/dom.13487

Title: Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes : A single-centre randomized controlled study
Author: Matikainen, Niina; Söderlund, Sanni; Björnson, Elias; Pietiläinen, Kirsi; Hakkarainen, Antti; Lundbom, Nina; Taskinen, Marja-Riitta; Boren, Jan
Contributor: University of Helsinki, Clinicum
University of Helsinki, Faculty of Medicine
University of Helsinki, Department of Medicine
University of Helsinki, Department of Diagnostics and Therapeutics
University of Helsinki, Department of Diagnostics and Therapeutics
University of Helsinki, Clinicum
Date: 2019-01
Language: eng
Number of pages: 11
Belongs to series: Diabetes, obesity and metabolism
ISSN: 1462-8902
URI: http://hdl.handle.net/10138/308850
Abstract: Aims Patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) exhibit considerable residual risk for cardiovascular disease (CVD). There is, therefore, increasing interest in targeting postprandial lipid metabolism and remnant cholesterol. Treatment with the glucagon-like peptide 1 (GLP-1) analogue liraglutide reduces CVD risk by mechanisms that remain unexplained in part. Here we investigated the effects of liraglutide intervention on ectopic fat depots, hepatic lipogenesis and fat oxidation, postprandial lipid metabolism and glycaemia in humans with type 2 diabetes. Methods The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes. Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks. Because liraglutide is known to promote weight loss, the study included dietary counselling to achieve similar weight loss in the liraglutide and placebo groups. Cardiometabolic responses to a high-fat mixed meal were measured before and at the end of the liraglutide intervention. Results Weight loss at Week 16 was similar between the groups: -2.4 kg (-2.5%) in the liraglutide group and -2.1 kg (-2.2%) in the placebo group. HBA1c improved by 6.4 mmol/mol (0.6%) in the liraglutide group (P = 0.005). Liver fat decreased in both groups, by 31% in the liraglutide group and by 18% in the placebo group, but there were no significant changes in the rate of hepatic de novo lipogenesis or beta-hydroxybutyrate levels, a marker of fat oxidation. We observed significant postprandial decreases in triglycerides only in plasma, chylomicrons and VLDL, and remnant particle cholesterol after treatment in the liraglutide group. Fasting and postprandial apoCIII concentrations decreased after liraglutide intervention and these changes were closely related to reduced glycaemia. In relative importance analysis, approximately half of the changes in postprandial lipids were explained by reductions in apoCIII concentrations, whereas less than 10% of the variation in postprandial lipids was explained by reductions in weight, glycaemic control, liver fat or postprandial insulin responses. Conclusions Intervention with liraglutide for 16 weeks produces multiple improvements in cardiometabolic risk factors that were not seen in the placebo group, despite similar weight loss. Of particular importance was a marked reduction in postprandial atherogenic remnant particles. The underlying mechanism may be improved glycaemic control, which leads to reduced expression of apoCIII, a key regulator of hypertriglyceridaemia in hyperglycaemic patients.
Subject: apolipoprotein C3
atherogenic dyslipidaemia
de novo lipogenesis
GLP-1-agonist
liraglutide
liver fat
postprandial lipids
remnant lipoproteins
FATTY LIVER-DISEASE
REMNANT CHOLESTEROL
VILDAGLIPTIN THERAPY
RECEPTOR AGONISTS
TRIGLYCERIDE
LIPOPROTEINS
METFORMIN
EXENATIDE
PARTICLES
PLACEBO
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Matikainen_et_a ... Obesity_and_Metabolism.pdf 1.157Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record